Zealand Pharma A/S (FRA:22Z)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.06B -52.2% |
| Revenue (ttm) | 621.14M -49.0% |
| Net Income | 366.63M -59.0% |
| EPS | 5.16 -58.9% |
| Shares Out | n/a |
| PE Ratio | 5.96 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25 |
| Open | 30.66 |
| Previous Close | 30.65 |
| Day's Range | 30.66 - 30.75 |
| 52-Week Range | 29.38 - 73.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
News
Zealand Pharma's ZP9830 Shows Favorable Tolerability In Phase 1 Trial
(RTTNews) - Monday, Zealand Pharma A/S (ZEAL.CO) announced positive topline results from the multiple ascending dose (MAD) portion of its Phase 1 trial evaluating ZP9830, an investigational Kv1.3 ion ...
Zealand Pharma announces results from ZP9830 trial
Zealand Pharma (ZLDPF) announced Phase 1 multiple ascending dose, or MAD, topline results for the company’s Kv1.3 ion channel blocker, ZP9830. The MAD part of the first-in-human, single-center, random...
Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic Diseases
(RTTNews) - Artificial intelligence is playing an increasingly important role in drug development, and Zealand Pharma (ZEAL) and Generate Biomedicines are the latest companies to combine their experti...
Zealand Pharma, Generate Biomedicines Partner To Develop AI-Designed Metabolic Disease Therapies
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, announced a multi-target strategic collaboration with Generate Biomedicines Inc. (GENB) to design and develop multispecific protein t...
Generate Biomedicines (GENB) Partners with Zealand Pharma to Advance Protein Therapeutics
Generate Biomedicines (GENB) Partners with Zealand Pharma to Advance Protein Therapeutics
Generate Biomedicines (GENB) Partners with Zealand Pharma to Develop Proteins for Obesity and ...
Generate Biomedicines (GENB) Partners with Zealand Pharma to Develop Proteins for Obesity and Metabolic Disorders
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion
Zealand Pharma and Generate Biomedicines said on Tuesday they have partnered to develop protein-based treatments for obesity and other metabolic diseases using AI, in a deal worth up to nearly $1.2 bi...
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Generate Biomedicines (GENB) announced a multi-target strategic collaboration with Zealand Pharma (ZLDPF). Under the collaboration, the companies intend to design and develop multispecific protein the...
Zealand Pharma (ZLDPF) Reports Promising Phase 2 Trial Results for Petrelintide in Type 2 Diabetes
Zealand Pharma (ZLDPF) Reports Promising Phase 2 Trial Results for Petrelintide in Type 2 Diabetes
Zealand Reports Improved Weight Reduction With Petrelintide In Phase 2 ZUPREME-2 Study
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, reported on Wednesday promising topline results from the Phase 2 ZUPREME-2 trial evaluating petrelintide in treating obese or overwei...
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Zealand Pharma said on Wednesday its experimental drug helped people who are overweight or obese and have type 2 diabetes lose up to 9.2% of their body weight in a mid-stage trial. The Danish company ...
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
Press release - No. 19 / 2026 Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a le...
Zealand Pharma opens research hub in Cambridge, Massachusetts
Zealand Pharma (ZLDPF) celebrated the opening of its new research hub at 35 CambridgePark Drive in Cambridge, Massachusetts, with a ribbon-cutting ceremony. The site, first announced in March 2026, is...
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface
Nearly one in five patients quit Zealand Pharma's late-stage survodutide trial due to gastrointestinal side effects caused by the obesity drug, data released on Thursday showed, again raising invest...
Zealand Pharma: Boehringer's Survodutide Delivers Up To 13.1% Weight Loss In Phase 3
(RTTNews) - Thursday, Zealand Pharma A/S (ZEAL.CO) announced new Phase 3 data for Survodutide, an investigational once-weekly glucagon/GLP-1 receptor dual agonist in patients with obesity, and type 2 ...
Zealand Pharma: Boehringer's Survodutide Meets Phase 3 Endpoints In Obesity & Diabetes Trial
(RTTNews) - Zealand Pharma A/S (ZEAL.CO) said Thursday that Boehringer Ingelheim's investigational Survodutide met its co-primary endpoints in the Phase 3 SYNCHRONIZE-2 trial in adults with obesity or...
Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Company announcement - No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glyc...
Zealand Publishes New Phase 2 Data For Petrelintide Showing Improved Cardiometabolic Benefits
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, on Wednesday announced the publication of new results from the Phase 3 ZUPREME-1 trial for Petrelintide in weight management. The dat...
Zealand announces initiation of registrational Phase 3 ZUPREME program
Zealand Pharma (ZLDPF) announces the initiation of the global registrational Phase 3 ZUPREME program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overw...
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
Zealand Pharma received a positive opinion from the Committee for Medicinal Products for Human Use recommending approval of its drug candidate Zeydovio for the treatment of short bowel syndrome, the...
Zealand Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted ambitious growth plans in metabolic health, with a focus on launching petrelintide and advancing combination therapies for obesity, supported by strong partnerships with Roche and Boehringer. Key rare disease assets and an expanding early-stage pipeline underscore a strategy centered on innovation, patient-centricity, and upcoming pivotal data and regulatory milestones.
Elvinix announces exclusive license agreement with Zealand Pharma
Elvinix announced an exclusive license agreement with Zealand Pharma (ZLDPF), granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio. Under the...
Zealand Pharma downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Zealand Pharma (ZLDPF) to Equal Weight from Overweight with a price target of DKK 330, down from DKK 425. The company has a “lean slate” of potential catalysts…
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
JPMorgan lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 435 from DKK 460 and keeps an Overweight rating on the shares.
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma
Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma’s economics related to rusfertide, a potential...